• Alicia Gonzalez-Martinez, Álvaro Planchuelo-Gómez, Ángel L Guerrero, David García-Azorín, Sonia Santos-Lasaosa, Navarro-PérezMaría PilarMPHeadache Unit, Department of Neurology, Hospital Clínico Universitario Lozano Blesa and Aragon Institute for Health Research (IIS Aragón), Zaragoza, Spain., Paula Odriozola-González, María Jesús Irurtia, Sonia Quintas, Rodrigo de Luis-García, and Ana Beatriz Gago-Veiga.
• Headache Unit, Department of Neurology, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain.
• Neurol. Sci. 2021 Dec 1; 42 (12): 5087-5092.

BackgroundFace-to-face procedures have been postponed during COVID-19 pandemic. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.MethodsSubjective worsening, intensity of migraine attacks, and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.ResultsWe included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0%) female, 44.5 ± 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 7.6 and 8.1 less monthly days with headache (adjusted p = 0.017) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.ConclusionInvoluntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.© 2021. Fondazione Società Italiana di Neurologia.

23 keywords...

hide…